MX2020012532A - Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). - Google Patents
Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela).Info
- Publication number
- MX2020012532A MX2020012532A MX2020012532A MX2020012532A MX2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A MX 2020012532 A MX2020012532 A MX 2020012532A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- als
- methods
- same
- lateral sclerosis
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678316P | 2018-05-31 | 2018-05-31 | |
| PCT/IL2019/050619 WO2019229757A1 (en) | 2018-05-31 | 2019-05-30 | Compositions and methods of using same for treating amyotrophic lateral sclerosis (als) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012532A true MX2020012532A (es) | 2021-04-28 |
Family
ID=68697171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012532A MX2020012532A (es) | 2018-05-31 | 2019-05-30 | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210100869A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3785279A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7350019B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019277920A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL279108B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020012532A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019229757A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| HUP0003349A3 (en) | 1997-05-14 | 2001-12-28 | Aventis Pharmaceuticals Inc Co | Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use |
| AU8726201A (en) * | 2000-03-31 | 2001-10-08 | Smithkline Beecham Plc | Use of CRF receptor agonists for the treatment of prophylaxis of diseases, for example neurodegenerative diseases |
| US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
| AU2005276117C1 (en) | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| WO2006046109A1 (en) * | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2008057609A2 (en) * | 2006-11-10 | 2008-05-15 | Genervon Biopharmaceuticals Llc | Methods of treating neuronal disorders using mntf peptides and analogs thereof |
| CN101677948A (zh) * | 2007-06-07 | 2010-03-24 | 纳斯泰克制药公司 | 卡贝缩宫素鼻用制剂和治疗孤独症的方法 |
| CA2836503C (en) * | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
| WO2016077687A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
-
2019
- 2019-05-30 JP JP2020565903A patent/JP7350019B2/ja active Active
- 2019-05-30 AU AU2019277920A patent/AU2019277920A1/en not_active Abandoned
- 2019-05-30 IL IL279108A patent/IL279108B2/en unknown
- 2019-05-30 EP EP19811026.4A patent/EP3785279A4/en active Pending
- 2019-05-30 WO PCT/IL2019/050619 patent/WO2019229757A1/en not_active Ceased
- 2019-05-30 MX MX2020012532A patent/MX2020012532A/es unknown
-
2020
- 2020-11-26 US US17/105,557 patent/US20210100869A1/en active Pending
-
2025
- 2025-02-14 AU AU2025201060A patent/AU2025201060A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210100869A1 (en) | 2021-04-08 |
| EP3785279A1 (en) | 2021-03-03 |
| EP3785279A4 (en) | 2022-07-27 |
| WO2019229757A1 (en) | 2019-12-05 |
| JP7350019B2 (ja) | 2023-09-25 |
| AU2019277920A1 (en) | 2021-01-07 |
| IL279108B2 (en) | 2024-10-01 |
| AU2025201060A1 (en) | 2025-03-20 |
| JP2021524858A (ja) | 2021-09-16 |
| IL279108B1 (en) | 2024-06-01 |
| IL279108A (en) | 2021-01-31 |
| CA3099846A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430398B1 (ar) | Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد | |
| MX2020004969A (es) | Composiciones y procedimientos para tratar cancer. | |
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| EP4349361A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| WO2012012600A3 (en) | Peptide compounds for regulating the complement system | |
| NZ708990A (en) | Method for activating helper t cell | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| MX2015014668A (es) | Angiotensinas en la distrofia muscular. | |
| FI3998067T3 (fi) | Koostumukset ja menetelmät homokystinurian hoitoon | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| WO2021067611A3 (en) | Compositions and methods for treating alzheimer's disease | |
| MX2020012532A (es) | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). | |
| RU2015119472A (ru) | Терапевтическое средство для бокового амиотрофического склероза | |
| ZA202401042B (en) | Protein compositions for the treatment of inflammatory diseases |